Evidence mapPaperPMID 41596449Full record

SynthesisInternational journal of molecular sciences2026

Artificial Intelligence-Driven Transformation of Pediatric Diabetes Care: A Systematic Review and Epistemic Meta-Analysis of Diagnostic, Therapeutic, and Self-Management Applications.

Estefania Valdespino-Saldaña, Nelly F Altamirano-Bustamante, Raúl Calzada-León, Cristina Revilla-Monsalve, Myriam M Altamirano-Bustamante

Abstract readSystematic ReviewMeta-AnalysisReview
In one paragraph

Synthesis in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Technology in Diabetes: A Year in Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Estefania Valdespino-SaldañaMetabolic Diseases Research Unit, National Medical Center "Siglo XXI", Mexican Social Security Institute (IMSS), Av. Cuauhtémoc, 330, Col. Doctores, Mexico City 06720, Mexico.
Nelly F Altamirano-BustamanteEndocrinology Department, National Institute of Pediatrics (INP), Av. Insurgentes Sur 3700, Mexico City 04530, Mexico.
Raúl Calzada-LeónEndocrinology Department, National Institute of Pediatrics (INP), Av. Insurgentes Sur 3700, Mexico City 04530, Mexico.ORCID 0000-0003-4253-4281
Cristina Revilla-MonsalveMetabolic Diseases Research Unit, National Medical Center "Siglo XXI", Mexican Social Security Institute (IMSS), Av. Cuauhtémoc, 330, Col. Doctores, Mexico City 06720, Mexico.ORCID 0000-0002-6202-1160
Myriam M Altamirano-BustamanteMetabolic Diseases Research Unit, National Medical Center "Siglo XXI", Mexican Social Security Institute (IMSS), Av. Cuauhtémoc, 330, Col. Doctores, Mexico City 06720, Mexico.ORCID 0000-0001-7297-4689

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The limitations of conventional diabetes management are increasingly evident. As a result, both type 1 and 2 diabetes in pediatric populations have become major global health concerns. As new technologies emerge, particularly artificial intelligence (AI), they offer new opportunities to improve diagnostic accuracy, treatment outcomes, and patient self-management. A PRISMA-based systematic review was conducted using PubMed, Web of Science, and BIREME. The research covered studies published up to February 2025, where twenty-two studies met the inclusion criteria. These studies examined machine learning algorithms, continuous glucose monitoring (CGM), closed-loop insulin delivery systems, telemedicine platforms, and digital educational interventions. AI-driven interventions were consistently associated with reductions in HbA1c and extended time in range. Furthermore, they reported earlier detection of complications, personalized insulin dosing, and greater patient autonomy. Predictive models, including digital twins and self-learning neural networks, significantly improved diagnostic accuracy and early risk stratification. Digital health platforms enhanced treatment adherence. Nonetheless, the barriers included unequal access to technology and limited long-term clinical validation. Artificial intelligence is progressively reshaping pediatric diabetes care toward a predictive, preventive, personalized, and participatory paradigm. Broader implementation will require rigorous multiethnic validation and robust ethical frameworks to ensure equitable deployment.

Indexed as

Artificial IntelligenceDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Self-ManagementBlood Glucose Self-MonitoringChildHumansInsulinMachine LearningTelemedicineInsulinartificial intelligenceclosed-loop insulin deliverycontinuous glucose monitoringdigital healthmachine learningpediatric diabetes

Identifiers

PMID41596449
PMCPMC12841495

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.